Olmesartan/hydrochlorothiazide
| Combination of | |
|---|---|
| Hydrochlorothiazide | Thiazide diuretic |
| Olmesartan | Angiotension receptor blocker |
| Names | |
| Trade names | Benicar HCT, Benitec H, others |
| Clinical data | |
| Routes of use | By mouth |
| Defined daily dose | not established[1] |
| Legal | |
| Legal status |
|
Olmesartan/hydrochlorothiazide, sold under the brand name Benicar HCT among others, is a medication used to treat high blood pressure.[2] It is a combination of olmesartan, an angiotension receptor blocker and hydrochlorothiazide, a diuretic.[2] It may be used if olmesartan is not sufficient to manage blood pressure.[3] It is taken by mouth.[3]
Common side effects include nausea, dizziness, and upper respiratory tract infections.[4] Serious side effects may include kidney problems, allergic reactions, electrolyte problems and low blood pressure.[4] Use in pregnancy is not recommended.[4] Olmesartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by increasing the loss of sodium by the kidneys.[4]
No generic version is available in the United States as of 2017.[2] A month supply in the United Kingdom costs the NHS about 13 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$6.[5] In 2017, it was the 292nd most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]
Dosage
The defined daily dose is not established[1]
Society and culture
Cost
A month supply in the United Kingdom costs the NHS about 13 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$6.[5] In 2017, it was the 292nd most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]
-
.svg.png)
Olmesartan/hydrochlorothiazide costs (US) -
.svg.png)
Olmesartan/hydrochlorothiazide prescriptions (US)
References
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020. Archived 1 July 2021 at the Wayback Machine
- ↑ 2.0 2.1 2.2 Bope, Edward T.; Kellerman, Rick D. (2016). Conn's Current Therapy 2017 E-Book. Elsevier Health Sciences. p. 124. ISBN 9780323443357. Archived from the original on 2019-12-19. Retrieved 2019-03-10.
- ↑ 3.0 3.1 3.2 3.3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 177–178. ISBN 9780857113382.
- ↑ 4.0 4.1 4.2 4.3 "Olmesartan Medoxomil and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 18 December 2019. Retrieved 11 March 2019. Archived 18 December 2019 at the Wayback Machine
- ↑ 5.0 5.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019. Archived 2019-03-06 at the Wayback Machine
- ↑ 6.0 6.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020. Archived 12 February 2021 at the Wayback Machine
- ↑ 7.0 7.1 "Hydrochlorothiazide; Olmesartan Medoxomil - Drug Usage Statistics". ClinCalc. Archived from the original on 26 September 2020. Retrieved 11 April 2020. Archived 26 September 2020 at the Wayback Machine
External links